Inositol in pregnancy: evidence and safety

How does inositol work?

Inositol is a polyol found naturally in animal and plant cells, and it works as scaffolding for signaling rather than acting on a target itself. The meta-analysis behind this page describes inositol as the structural basis for a variety of second messengers in eukaryotic cells, which puts it in the transduction path for several endocrine signals including FSH, TSH, and insulin. On the insulin side specifically, myo-inositol and D-chiro-inositol are described as insulin sensitizers that increase GLUT4 translocation to the cell membrane and act through the PI3K/AKT pathway, lowering insulin resistance and plasma glucose. That signaling account is the rationale offered for the gestational diabetes trials, which measured outcomes rather than mechanism, so it remains a proposed pathway rather than something demonstrated in pregnant human tissue.

What does the evidence say about inositol in pregnancy?

• Across six trials of 1,140 women, myo-inositol was associated with a lower rate of gestational diabetes (risk ratio 0.53, 95 percent CI 0.31 to 0.90), but the Cochrane reviewers rated the certainty of that evidence low to very low. 1
• Five of the studies that measured safety reported no adverse effects of therapy, across seven different formulations ranging from 200 mg to 4 g of myo-inositol daily, usually combined with folic acid and sometimes D-chiro-inositol. 1
• For women who already have gestational diabetes, the evidence is thinner still: only two Italian trials of 142 women, both using 4 g myo-inositol plus 400 mcg folic acid, with Cochrane concluding there is insufficient data and noting adverse effects were not reported in the included trials. 2
• A separate meta-analysis of seven randomized trials and 1,321 participants found 4 g of myo-inositol daily associated with a 70 percent lower rate of gestational diabetes (RR 0.30), while rating the evidence very low and flagging that six of the studies came from Italy. 3
• The UK EMmY pilot randomized 198 women to 2 g of myo-inositol twice daily and found gestational diabetes rates of 14.1 percent versus 13.1 percent for control. Vomiting was reported by 15.1 percent of the myo-inositol group versus 9.1 percent of controls, and adherence fell to 34 percent by 36 weeks. 4

What's on the label?

Products differ mainly in the myo-inositol to D-chiro-inositol ratio, and only two configurations carry pregnancy data. Across the trials pooled in that meta-analysis, six used 4 g of myo-inositol daily and two used 1.1 g of myo-inositol plus 27.6 mg of D-chiro-inositol. Inositol exists in nine stereoisomeric forms, of which myo-inositol and D-chiro-inositol are the two most common in human cells, so a label naming anything else is outside the studied range.

What should I know before taking inositol?

Please consult your healthcare provider before adding this supplement to a prenatal regimen, particularly if you are on prescription medication or have a scheduled procedure. Supplement contents are not FDA-verified, so a labeled dose and an actual dose can differ; look for third-party-tested brands.